AGP Executive Report
Last update: 9 hours agoPediatric GLP-1 Surge: Prescribing of GLP-1 weight-loss drugs among U.S. children ages 8–11 with obesity jumped from 0.03% (2019) to 9.3% by June 2026, despite no FDA obesity approval under 12, raising questions about off-label use and access. Medical Devices Recall: The FDA added multiple Philips CT systems (IQon, iCT, Ingenuity, Brilliance CT 64) to a recall list due to an “unintended radiation issue,” with Philips saying a free software fix will address it. Oncology & Immunotherapy Advances: FDA approval spotlighted new options in multiple myeloma (iberdomide/Zenbexus as a CELMoD) and essential thrombocythemia (ropeginterferon alfa-2b-njft/BESREMi), signaling continued momentum in targeted blood cancer care. Community Pharmacy Leadership: NCPA named Sara Roszak senior vice president for the CEO’s office, including responsibility for AI strategy and independent pharmacy initiatives. Neurogenetics Breakthrough: New research identified 36 shared risk genes linking OCD, Tourette syndrome, and autism-related biology. Health Policy & Industry: India’s Piyush Goyal said the government is ready to fund 100% of top medical testing equipment costs and push shared lab infrastructure to attract global device makers.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
